Cargando…

Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy

Despite antiretroviral therapy, proviral latency of human immunodeficiency virus type 1 (HIV-1) remains a principal obstacle to curing the infection [1]. Inducing the expression of latent genomes within resting CD4+ T cells is the primary strategy to clear this reservoir [2]. While histone deacetyla...

Descripción completa

Detalles Bibliográficos
Autores principales:	Archin, NM, Liberty, AL, Kashuba, AD, Choudhary, SK, Kuruc, JD, Crooks, AM, Parker, DC, Anderson, EM, Kearney, MF, Strain, MC, Richman, DD, Hudgens, MG, Bosch, RJ, Coffin, JM, Eron, JJ, Hazuda, DJ, Margolis, DM
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2012
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3704185/ https://www.ncbi.nlm.nih.gov/pubmed/22837004 http://dx.doi.org/10.1038/nature11286

Ejemplares similares

The differential short- and long-term effects of HIV-1 latency-reversing agents on T cell function
por: Clutton, G., et al.
Publicado: (2016)

Corrigendum: The differential short- and long-term effects of HIV-1 latency-reversing agents on T cell function
por: Clutton, G., et al.
Publicado: (2016)

Vorinostat Renders the Replication-Competent Latent Reservoir of Human Immunodeficiency Virus (HIV) Vulnerable to Clearance by CD8 T Cells
por: Sung, Julia A., et al.
Publicado: (2017)

Assessing the impact of AGS-004, a dendritic cell-based immunotherapy, and vorinostat on persistent HIV-1 Infection
por: Gay, Cynthia L., et al.
Publicado: (2020)

Cellular Gene Modulation of HIV-Infected CD4 T Cells in Response to Serial Treatment with the Histone Deacetylase Inhibitor Vorinostat
por: Maxwell, Jill W., et al.
Publicado: (2020)

Vorinostat—An Overview
por: Bubna, Aditya Kumar
Publicado: (2015)

Peripheral Vγ9Vδ2 T Cells Are a Novel Reservoir of Latent HIV Infection
por: Soriano-Sarabia, Natalia, et al.
Publicado: (2015)

Phospholipase D1 is upregulated by vorinostat and confers resistance to vorinostat in glioblastoma
por: Kang, Dong Woo, et al.
Publicado: (2020)

Antiretroviral Intensification and Valproic Acid Lack Sustained Effect on Residual HIV-1 Viremia or Resting CD4+ Cell Infection
por: Archin, Nancie M., et al.
Publicado: (2010)

HIV-1 infection, response to treatment and establishment of viral latency in a novel humanized T cell-only mouse (TOM) model
por: Honeycutt, Jenna B, et al.
Publicado: (2013)

Dominant CD4(+) T cell receptors remain stable throughout antiretroviral therapy-mediated immune restoration in people with HIV
por: Sponaugle, Alexis, et al.
Publicado: (2023)

Vorinostat in solid and hematologic malignancies
por: Siegel, David, et al.
Publicado: (2009)

New Concepts in Therapeutic Manipulation of HIV-1 Transcription and Latency: Latency Reversal versus Latency Prevention
por: Lewis, Catherine A., et al.
Publicado: (2023)

Antioxidants Impair Anti-Tumoral Effects of Vorinostat, but Not Anti-Neoplastic Effects of Vorinostat and Caspase-8 Downregulation
por: Bergadà, Laura, et al.
Publicado: (2014)

Vorinostat (SAHA) and Breast Cancer: An Overview
por: Wawruszak, Anna, et al.
Publicado: (2021)

Clinical Efficacy of Vorinostat in a Patient with Leiomyosarcoma
por: Lee, Jin, et al.
Publicado: (2012)

The Effect of Vorinostat on the Development of Resistance to Doxorubicin in Neuroblastoma
por: Lautz, Timothy B., et al.
Publicado: (2012)

Immune effectors required for the therapeutic activity of vorinostat
por: Kepp, Oliver, et al.
Publicado: (2013)

Differential Response of Mycosis Fungoides Cells to Vorinostat
por: Bordeaux, Zachary A., et al.
Publicado: (2023)

Evaluation of EED Inhibitors as a Class of PRC2-Targeted Small Molecules for HIV Latency Reversal
por: Turner, Anne-Marie W., et al.
Publicado: (2020)

Activation of HIV Transcription with Short-Course Vorinostat in HIV-Infected Patients on Suppressive Antiretroviral Therapy
por: Elliott, Julian H., et al.
Publicado: (2014)

Vorinostat synergises with capecitabine through upregulation of thymidine phosphorylase
por: Di Gennaro, E, et al.
Publicado: (2010)

The synergic effect of vincristine and vorinostat in leukemia in vitro and in vivo
por: Chao, Min-Wu, et al.
Publicado: (2015)

Direct but No Transgenerational Effects of Decitabine and Vorinostat on Male Fertility
por: Kläver, Ruth, et al.
Publicado: (2015)

Vorinostat in the acute neuroinflammatory form of X‐linked adrenoleukodystrophy
por: Zierfuss, Bettina, et al.
Publicado: (2020)

Methotrexate/tacrolimus/vorinostat: Lack of efficacy: case report
Publicado: (2022)

A truncated HIV Tat demonstrates potent and specific latency reversal activity
por: Van Gulck, Ellen, et al.
Publicado: (2023)

Chromatin Regulation and the Histone Code in HIV Latency 
por: Turner, Anne-Marie W., et al.
Publicado: (2017)

Measuring the Inducible, Replication-Competent HIV Reservoir Using an Ultra-Sensitive p24 Readout, the Digital ELISA Viral Outgrowth Assay
por: Stuelke, Erin L., et al.
Publicado: (2020)

HIV-Specific T Cell Responses Are Highly Stable on Antiretroviral Therapy
por: Xu, Yinyan, et al.
Publicado: (2019)

Update on the treatment of cutaneous T-cell lymphoma (CTCL): Focus on vorinostat
por: Duvic, Madeleine, et al.
Publicado: (2007)

Vorinostat enhances the anticancer effect of oxaliplatin on hepatocellular carcinoma cells
por: Liao, Bo, et al.
Publicado: (2017)

Fluvastatin potentiates anticancer activity of vorinostat in renal cancer cells
por: Okubo, Kazuki, et al.
Publicado: (2019)

Vorinostat approved in Japan for treatment of cutaneous T-cell lymphomas: status and prospects
por: Sato, Akinori
Publicado: (2012)

Vorinostat Induces Apoptosis and Differentiation in Myeloid Malignancies: Genetic and Molecular Mechanisms
por: Silva, Gabriela, et al.
Publicado: (2013)

Vorinostat in combination with lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma
por: Siegel, D S, et al.
Publicado: (2014)

Vorinostat in combination with lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma
por: Siegel, D S, et al.
Publicado: (2014)

Vorinostat enhances chemosensitivity to arsenic trioxide in K562 cell line
por: Li, Nainong, et al.
Publicado: (2015)

The HDAC Inhibitor Vorinostat Diminishes the In Vitro Metastatic Behavior of Osteosarcoma Cells
por: Mu, Xiaodong, et al.
Publicado: (2015)

Vorinostat protects against calcium oxalate-induced kidney injury in mice
por: WANG, LI, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_dcmjer0d5eup80l4ooqr6tr13o